A method for cycloaddition of dimethyl muconate is disclosed. According to the method, a direct transferring of a solid phase trans,trans-dimehtyl muconate into a reactor pre-filled with ethylene gas increases the efficiency of the reaction and suppress side reactions resulting an improvements in yield and purity. Furthermore, the method is capable of obtaining a high yield of dimethylcyclohex-2-en-1,4-dicarboxylate at a lower cost, and therefore is also useful for the mass synthesis of dimethyl terephthalate.

A method for cycloaddition of dimethyl muconate is disclosed. According to the method, a direct transferring of a solid phase trans,trans-dimehtyl muconate into a reactor pre-filled with ethylene gas increases the efficiency of the reaction and suppress side reactions resulting an improvements in yield and purity. Furthermore, the method is capable of obtaining a high yield of dimethylcyclohex-2-en-1,4-dicarboxylate at a lower cost, and therefore is also useful for the mass synthesis of dimethyl terephthalate.

This disclosure provides a nonaqueous coolant composition excellent in insulation property and heat transfer characteristic. The embodiment is a coolant composition that includes at least one carboxylic acid ester compound as a nonaqueous base and is substantially free of water.

This disclosure provides a nonaqueous coolant composition excellent in insulation property and heat transfer characteristic. The embodiment is a coolant composition that includes at least one carboxylic acid ester compound as a nonaqueous base and is substantially free of water.

Biologically active cannabidiol analogs comprising a compound of the formula

##STR00001##

wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Biologically active cannabidiol analogs comprising a compound of the formula

##STR00001##

wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

The present disclosure is drawn to methods of treating diseases or disorders, and uses of preparing medicaments. The methods of administering and/or preparation of medicaments can include the use of a compound of Formula (I) disclosed herein, or a geometric isomer, stereoisomer, and/or pharmaceutically acceptable salt or solvate thereof.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.

##STR00001##

A method for cycloaddition of dimethyl muconate is disclosed. According to the method, a direct transferring of a solid phase trans,trans-dimehtyl muconate into a reactor pre-filled with ethylene gas increases the efficiency of the reaction and suppress side reactions resulting an improvements in yield and purity. Furthermore, the method is capable of obtaining a high yield of dimethylcyclohex-2-en-1,4-dicarboxylate at a lower cost, and therefore is also useful for the mass synthesis of dimethyl terephthalate.

Disclosed in the present invention are an emodin succinyl ester compound, a preparation method therefor and a use thereof, the emodin succinyl ester compound having the structure as represented by formula I (R being a C.sub.1-5 alkyl group). The method provided in the present invention has a simple method course, and may effectively save time in synthesis and reduce costs, being simple to operate, being easy to implement, and being suitable for industrial production. Experiments show that the emodin succinyl ester compound of the present invention may better promote the healing of diabetic wounds than emodin, and may be used for preparing a drug for promoting the healing of diabetic wounds. Moreover, it has been confirmed by means of performing pharmacological experiments on rats suffering from experimentally mixed hyperlipidemia that the emodin succinyl ester compound of the present invention is superior to emodin, and has the advantages of having a remarkable blood fat lowering effect, being safe, being simple and convenient to administer, the raw materials being low cost and readily available, and being easy to transport and store.